Therefore, we concluded that HSF1 is a promising therapeutic target and KRIBB11 or emetine can be used as a lead compound to develop a therapeutic drug for overcoming EGFR-TKIs resistance in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.